MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 20...

MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, Moon...

SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

If you're looking for some of the hottest opportunities on the market, consider some of the best momentum stocks to buy. After all, momentum investors try to ride the highs no matter what happens.

The consensus price target hints at a 27% upside potential for MoonLake Immunotherapeutics (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

MoonLake Immunotherapeutics (MLTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hid...

MoonLake Immunotherapeutics shares swooned Monday after the company reported ambiguous results for its psoriatic arthritis treatment.  Patients who received MoonLake's drug, sonelokimab, did show stat...

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnol...

MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa. Sonelokimab has shown promising results in treati...

MoonLake is a clinical-stage biotech that focuses on inflammatory diseases. Its lead therapy, sonelokimab, is being tested against several conditions.

MoonLake shares rocketed Tuesday after rival Acelyrin reported a failure for its skin disease treatment. MLTX stock neared a record.

Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum i...

MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokimab's potential in treating HS, collaborating with S...

Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains ...

We continue with our recurring series based on analyzing mid-cap stocks that have enjoyed periods unusual insider interest during the second quarter of the year. An overwhelming trend of bank insiders...

MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.

Earlier this week, MoonLake Immunotherapeutics announced positive mid-stage results for its hidradenitis suppurativa treatment. The therapy could become the standard of care for this chronic skin cond...

Clinical stage biotech MoonLake Immunotherapeutics AG NASDAQ: MLTX shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies that c...